Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients

AIDS

Volumn 23, Issue 15, 2009, Pages 2021-2027

  Hsue, Priscilla Y ^a   Hunt, Peter W ^a   Wu, Yuaner ^a   Schnell, Amanda ^a   Ho, Jennifer E ^a   Hatano, Hiroyu ^a   Xie, Yu ^a   Martin, Jeffrey N ^a,b   Ganz, Peter ^a   Deeks, Steven G ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abacavir; Cardiovascular risk; Endothelial function; Treated HIV

Indexed keywords

ABACAVIR; BIOLOGICAL MARKER; CD4 ANTIGEN; DIDANOSINE; GLYCERYL TRINITRATE; TENOFOVIR; VIRUS RNA;

ADULT; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; ASSOCIATION; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CELL COUNT; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD;

ANTI-HIV AGENTS; BRACHIAL ARTERY; DIDEOXYNUCLEOSIDES; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VASODILATION; VIRAL LOAD;

EID: 70349769521     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832e7140     Document Type: Article

References (37)

1. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
2. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multicohort collaboration. Lancet 2008; 371:1417-1426.
3. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
4. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: A case-control study nested within FHDH ANRS CO4 [abstract #43LB]. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; 8-11 February 2009.
5. Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139-147.
6. Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005; 6:396-402.
7. Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007; 45:34-42.
8. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41:1769-1775.
9. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G, Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86:207-210.
10. Ganz P, Vita JA. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 2003; 108:2049-2053.
11. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111:363-368.
12. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dube MP, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569-576.
13. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002; 106:184-190.
14. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265.
15. Kinlay S, Behrendt D, Fang JC, Delagrange D, Morrow J, Witztum JL, et al. Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 2004; 43:629-634.
16. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, Creager MA. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 1996; 78:1210-1214
17. Stadler RW, Karl WC, Lees RS. New methods for arterial diameter measurement from B-mode images. Ultrasound Med Biol 1996; 22:25-34.
18. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006; 99:1426-1432.
19. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
20. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008; 196:720-726.
21. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. J Clin Endocrinol Metab 2007; 92:2506-2512.
22. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275-2283.
23. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
24. Reiss P. Abacavir and cardiovascular risk [abstract #152]. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; 2009.
25. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKlinesponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-28.
26. Benson C, Ribaudo H, Zheng E, Koletar S, Smurzynski M, Bosch RB, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001 [abstract #721]. Montreal, Canada; 2009.
27. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105:546-549. (Pubitemid 34123425)
28. Gokce N, Vita JA. Clinical manifestations of endothelial dysfunction. In: Loscalzo J, Schafer A, editors. Thrombosis and hemorrhage. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins; 2002. pp. 685-706.
29. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
30. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42:1149-1160.
31. Satchell C, O'Connor E, Peace A, Cotter A, Sheehan G, Tedesco T, et al. Platelet hyper-reactivity in HIV-1-infected patients on abacavir-containing ART [abstract 151LB]. Montreal, Canada; 2009.
32. Jin RC, Voetsch B, Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation 2005; 12:247-258.
33. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100:350-356.
34. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100:1673-1685.
35. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007; 115:2390-2397.
36. Mohiaddin RH, Burman ED, Prasad SK, Varghese A, Tan RS, Collins SA, et al. Glagov remodeling of the atherosclerotic aorta demonstrated by cardiovascular magnetic resonance: the CORDA asymptomatic subject plaque assessment research (CASPAR) project. J Cardiovasc Magn Reson 2004; 6:517-525.
37. van Vonderen MG, Hassink EA, van Agtmael MA, Stehouwer CD, Danner SA, Reiss P, Smulders Y. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009; 199:1186-1194.